Sign up
Pharma Capital

Medibio attracts sophisticated investors

The halt will remain in place until Friday 13th October 2017.
The company's shares are in pre-open

Medibio Ltd (ASX:MEB) is pioneering the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions.

Earlier in the week the company entered into an agreement with Otsuka Pharmaceutical Development & Commercialization, Inc. to process clinical data.

Medibio is now preparing to outline a placement to professional and sophisticated investors, with the ASX granting a trading halt to prepare.

The halt will remain in place until the opening of trade on Friday 13th October 2017, or earlier if an announcement is made to the market.

View full MEB profile View Profile

Medibio Ltd pockets funds for next phase

View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.